Adrian David Marais
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adrian David Marais has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Jacobus Blom
Division of Lipidology and Cape Heart Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa
7 shared publications D J Blom
Division of Lipidology and Cape Heart Institute, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
5 shared publicationsF J Raal
Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
4 shared publications- Frank L. J. Visseren
University Medical Center Utrecht
4 shared publications - Charlotte Koopal
Department of Vascular Medicine, University Medical Center Utrecht, Utrecht University , PO Box 85500, GA 3508, Utrecht
3 shared publications - Britt E. Heidemann
Department of Vascular Medicine University Medical Center Utrecht, Utrecht University Utrecht The Netherlands
2 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 116 (5) , e4971
LDL-cholesterol targets and lipid-lowering therapies – a plea to medical schemes and the Council for Medical Schemes
- 2 June 2026
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 116 (5) , e4971
Open AccessLDL-cholesterol targets and lipid-lowering therapies – a plea to medical schemes and the Council for Medical Schemes
- 18 December 2025
- Published by Springer Nature
- p. 1-38
Apolipoprotein E and Cholesterol Metabolism
- Open Access
- 24 July 2025
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 4 (3)
Discriminating dyslipidemias - a South African perspective
Clinical observation and scientific research have established that premature atherosclerotic vascular disease is strongly associated with markedly elevated low-density lipoprotein (LDL) cholesterol levels. Genetic disorders that impair LDL clearance via LDL receptors (LDLRs) are classified into heterozygous and homozygous familial hypercholesterolemia (FH) phenotypes. The heterozygous FH (HeFH) phenotype is characterized by LDL cholesterol levels exceeding 4.9 mmol/L, the presence of tendon xanthomas, and premature heart disease. In contrast, homozygous FH (HoFH) is characterised by LDL cholesterol levels above 13 mmol/L, both cutaneous and tendon xanthomas, and may lead to atherosclerotic vascular disease manifesting in childhood. FH is relatively common and occurs at even higher frequencies in populations founded by small ancestral groups, as documented in South Africa through investigations conducted in tertiary healthcare settings. Despite significant advances in the diagnosis and treatment of lipid and lipoprotein disorders - many of which are part of the differential diagnosis of FH - support for the diagnosis and management of FH has declined. While existing clinical guidelines address most cases of hypercholesterolemia, a subset of individuals with severe dyslipidemias requires more specialized evaluation. Referral criteria are proposed to help identify these patients. Given the high cardiovascular risk associated with severe hypercholesterolemia and the availability of effective treatments, there is an urgent need to strengthen, coordinate, and integrate clinical and laboratory services in South Africa to differentiate among the various causes of these disorders.
- 24 July 2025
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 4 (3)
Open AccessDiscriminating dyslipidemias - a South African perspective
Clinical observation and scientific research have established that premature atherosclerotic vascular disease is strongly associated with markedly elevated low-density lipoprotein (LDL) cholesterol levels. Genetic disorders that impair LDL clearance via LDL receptors (LDLRs) are classified into heterozygous and homozygous familial hypercholesterolemia (FH) phenotypes. The heterozygous FH (HeFH) phenotype is characterized by LDL cholesterol levels exceeding 4.9 mmol/L, the presence of tendon xanthomas, and premature heart disease. In contrast, homozygous FH (HoFH) is characterised by LDL cholesterol levels above 13 mmol/L, both cutaneous and tendon xanthomas, and may lead to atherosclerotic vascular disease manifesting in childhood. FH is relatively common and occurs at even higher frequencies in populations founded by small ancestral groups, as documented in South Africa through investigations conducted in tertiary healthcare settings. Despite significant advances in the diagnosis and treatment of lipid and lipoprotein disorders - many of which are part of the differential diagnosis of FH - support for the diagnosis and management of FH has declined. While existing clinical guidelines address most cases of hypercholesterolemia, a subset of individuals with severe dyslipidemias requires more specialized evaluation. Referral criteria are proposed to help identify these patients. Given the high cardiovascular risk associated with severe hypercholesterolemia and the availability of effective treatments, there is an urgent need to strengthen, coordinate, and integrate clinical and laboratory services in South Africa to differentiate among the various causes of these disorders.
- Open Access
- 10 June 2024
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 36 (10) , e13414
Dyslipidaemia in women with polycystic ovary syndrome referred to a teaching hospital in Cape Town, South Africa
The polycystic ovary syndrome (PCOS) imparts health risks including dyslipidaemia, diabetes and cardiovascular disease that are amenable to lifestyle adjustment and/or medication. We describe dyslipidaemia in women referred to a gynaecological endocrine clinic. Clinical data and endocrine and lipoprotein investigations comprising fasting triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDLC) and calculated low density lipoprotein cholesterol (LDLC) were studied along with electrophoresis patterns of apolipoprotein B‐containing lipoproteins. The 1721 participants comprised black, mixed ancestry, white and Indian individuals (9.8%, 83.2%, 5.8% and 1.2%, respectively). The mean ± standard deviation of the age, body mass index (BMI) and waist/hip ratio were 26.0 ± 5.9 years, 32.3 ± 8.3 kg/m2 and waist/hip ratio 0.88 ± 0.11, respectively. Overweight status (BMI 26–30 kg/m2) and obesity (BMI >30 kg/m2) involved 272 (15.8%) and 1010 (58.7%) individuals, respectively. Morbid obesity (BMI >40 kg/m2) was present in 309 (17.9%) individuals. The TG, TC, HDLC and LDLC concentrations were 1.22 ± 0.86, 4.77 ± 1.02, 1.3 ± 0.36, 2.94 ± 0.94 mmol/L, respectively. LDL hypercholesterolaemia occurred in 753 (43.7%) and exceeded 5 mmol/L in 39 (2.3%) women. Low HDLC (1.7 mmol/L) affected 265 (15.4%) and exceeded 2.5 mmol/L in 91 (5.3%) women. Mixed hyperlipidaemia (TG >1.7, TC >5.0 mmol/L) occurred in 176 (10.2%). Electrophoresis revealed small LDL particles in 79 (4.6%) and dysbetalipoproteinaemia in 13 (0.76%) of the cohort. Small LDL associated with obesity, blood pressure, TG and glucose concentration and higher androgenic state. Many women with PCOS had unfavourable lipoprotein results: mostly moderate changes in TG, HDLC and LDLC. Small LDL is not rare, may aid risk assessment and is best determined directly. Incidental monogenic disorders of lipoprotein metabolism included dysbetalipoproteinaemia, familial hypercholesterolaemia and severe hypertriglyceridaemia. Dyslipidaemia in PCOS requires more careful diagnosis, individualised management and research.
- 10 June 2024
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 36 (10) , e13414
Open AccessDyslipidaemia in women with polycystic ovary syndrome referred to a teaching hospital in Cape Town, South Africa
The polycystic ovary syndrome (PCOS) imparts health risks including dyslipidaemia, diabetes and cardiovascular disease that are amenable to lifestyle adjustment and/or medication. We describe dyslipidaemia in women referred to a gynaecological endocrine clinic. Clinical data and endocrine and lipoprotein investigations comprising fasting triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDLC) and calculated low density lipoprotein cholesterol (LDLC) were studied along with electrophoresis patterns of apolipoprotein B‐containing lipoproteins. The 1721 participants comprised black, mixed ancestry, white and Indian individuals (9.8%, 83.2%, 5.8% and 1.2%, respectively). The mean ± standard deviation of the age, body mass index (BMI) and waist/hip ratio were 26.0 ± 5.9 years, 32.3 ± 8.3 kg/m2 and waist/hip ratio 0.88 ± 0.11, respectively. Overweight status (BMI 26–30 kg/m2) and obesity (BMI >30 kg/m2) involved 272 (15.8%) and 1010 (58.7%) individuals, respectively. Morbid obesity (BMI >40 kg/m2) was present in 309 (17.9%) individuals. The TG, TC, HDLC and LDLC concentrations were 1.22 ± 0.86, 4.77 ± 1.02, 1.3 ± 0.36, 2.94 ± 0.94 mmol/L, respectively. LDL hypercholesterolaemia occurred in 753 (43.7%) and exceeded 5 mmol/L in 39 (2.3%) women. Low HDLC (1.7 mmol/L) affected 265 (15.4%) and exceeded 2.5 mmol/L in 91 (5.3%) women. Mixed hyperlipidaemia (TG >1.7, TC >5.0 mmol/L) occurred in 176 (10.2%). Electrophoresis revealed small LDL particles in 79 (4.6%) and dysbetalipoproteinaemia in 13 (0.76%) of the cohort. Small LDL associated with obesity, blood pressure, TG and glucose concentration and higher androgenic state. Many women with PCOS had unfavourable lipoprotein results: mostly moderate changes in TG, HDLC and LDLC. Small LDL is not rare, may aid risk assessment and is best determined directly. Incidental monogenic disorders of lipoprotein metabolism included dysbetalipoproteinaemia, familial hypercholesterolaemia and severe hypertriglyceridaemia. Dyslipidaemia in PCOS requires more careful diagnosis, individualised management and research.
- Open Access
- 18 March 2024
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 114 (3) , e1016
Management of hyperlipidaemia
- 18 March 2024
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 114 (3) , e1016
Open AccessManagement of hyperlipidaemia
- 21 June 2023
- Vol. 113 (7) , 6-7
Premature cardiovascular deaths.
- Open Access
- 29 October 2022
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (1) , 112-123
Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
- 29 October 2022
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (1) , 112-123
Open AccessEffect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
- Open Access
- 22 August 2022
- Published by Wiley in Clinical Genetics
- Vol. 102 (4) , 253-261
Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in theAPOEgene
Familial Dysbetalipoproteinemia (FD) is the second most common monogenic dyslipidemia and is associated with a very high cardiovascular risk due to cholesterol‐enriched remnant lipoproteins. FD is usually caused by a recessively inherited variant in theAPOEgene (ε2ε2), but variants with dominant inheritance have also been described. The typical dysbetalipoproteinemia phenotype has a delayed onset and requires a metabolic hit. Therefore, the diagnosis of FD should be made by demonstrating both the genotype and dysbetalipoproteinemia phenotype. Next Generation Sequencing is becoming more widely available and can reveal variants in theAPOEgene for which the relation with FD is unknown or uncertain. In this article, two approaches are presented to ascertain the relationship of a new variant in theAPOEgene with FD. The comprehensive approach consists of determining the pathogenicity of the variant and its causal relationship with FD by confirming a dysbetalipoproteinemia phenotype, and performingin vitrofunctional tests and, optionally,in vivopostprandial clearance studies. When this is not feasible, a second, pragmatic approach within reach of clinical practice can be followed for individual patients to make decisions on treatment, follow‐up, and family counseling.
- 22 August 2022
- Published by Wiley in Clinical Genetics
- Vol. 102 (4) , 253-261
Open AccessEstablishing the relationship between familial dysbetalipoproteinemia and genetic variants in theAPOEgene
Familial Dysbetalipoproteinemia (FD) is the second most common monogenic dyslipidemia and is associated with a very high cardiovascular risk due to cholesterol‐enriched remnant lipoproteins. FD is usually caused by a recessively inherited variant in theAPOEgene (ε2ε2), but variants with dominant inheritance have also been described. The typical dysbetalipoproteinemia phenotype has a delayed onset and requires a metabolic hit. Therefore, the diagnosis of FD should be made by demonstrating both the genotype and dysbetalipoproteinemia phenotype. Next Generation Sequencing is becoming more widely available and can reveal variants in theAPOEgene for which the relation with FD is unknown or uncertain. In this article, two approaches are presented to ascertain the relationship of a new variant in theAPOEgene with FD. The comprehensive approach consists of determining the pathogenicity of the variant and its causal relationship with FD by confirming a dysbetalipoproteinemia phenotype, and performingin vitrofunctional tests and, optionally,in vivopostprandial clearance studies. When this is not feasible, a second, pragmatic approach within reach of clinical practice can be followed for individual patients to make decisions on treatment, follow‐up, and family counseling.
- Open Access
- 1 May 2022
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 112 (5) , 307-312
Hypertriglyceridaemia in adolescents may have serious complications
Acute pancreatitis is an often-overlooked cause of acute abdominal pain in children and adolescents. Severe hypertriglyceridaemia is an important cause of recurrent acute pancreatitis. Monogenic causes of hypertriglyceridaemia, such as familial chylomicronaemia caused by lipoprotein lipase deficiency, are more frequently encountered in children and adolescents, but remain rare. Polygenic hypertriglyceridaemia is more common, but may require a precipitant before manifesting. With the global increase in obesity and type 2 diabetes, secondary causes of hypertriglyceridaemia in children and adolescents are increasing. We report two cases of severe hypertriglyceridaemia and pancreatitis in adolescent females. Hypertriglyceridaemia improved markedly with restriction of dietary fat. An inhibitor to lipoprotein lipase was found to be the cause in one patient, while in the other limited genetic investigation excluded chylomicronaemia owing to deficiency of lipoprotein lipase, its activators and processing proteins.
- 1 May 2022
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 112 (5) , 307-312
Open AccessHypertriglyceridaemia in adolescents may have serious complications
Acute pancreatitis is an often-overlooked cause of acute abdominal pain in children and adolescents. Severe hypertriglyceridaemia is an important cause of recurrent acute pancreatitis. Monogenic causes of hypertriglyceridaemia, such as familial chylomicronaemia caused by lipoprotein lipase deficiency, are more frequently encountered in children and adolescents, but remain rare. Polygenic hypertriglyceridaemia is more common, but may require a precipitant before manifesting. With the global increase in obesity and type 2 diabetes, secondary causes of hypertriglyceridaemia in children and adolescents are increasing. We report two cases of severe hypertriglyceridaemia and pancreatitis in adolescent females. Hypertriglyceridaemia improved markedly with restriction of dietary fat. An inhibitor to lipoprotein lipase was found to be the cause in one patient, while in the other limited genetic investigation excluded chylomicronaemia owing to deficiency of lipoprotein lipase, its activators and processing proteins.
- 30 March 2022
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 24 (6) , 399-405
Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms
Purpose of Review Lipoprotein (a) [Lp(a)] is a highly atherogenic lipoprotein species. A unique feature of Lp(a) is the strong genetic determination of its concentration. The LPA gene is responsible for up to 90% of the variance in Lp(a), but other genes also have an impact. Recent Findings Genome-wide associations studies indicate that the APOE gene, encoding apolipoprotein E (apoE), is the second most important locus modulating Lp(a) concentrations. Population studies clearly show that carriers of the apoE2 variant (ε2) display reduced Lp(a) levels, the lowest concentrations being observed in ε2/ε2 homozygotes. This genotype can lead predisposed adults to develop dysbetalipoproteinemia, a lipid disorder characterized by sharp elevations in cholesterol and triglycerides. However, dysbetalipoproteinemia does not significantly modulate circulating Lp(a). Mechanistically, apoE appears to impair the production but not the catabolism of Lp(a). Summary These observations underline the complexity of Lp(a) metabolism and provide key insights into the pathways governing Lp(a) synthesis and secretion.
- 30 March 2022
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 24 (6) , 399-405
Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms
Purpose of Review Lipoprotein (a) [Lp(a)] is a highly atherogenic lipoprotein species. A unique feature of Lp(a) is the strong genetic determination of its concentration. The LPA gene is responsible for up to 90% of the variance in Lp(a), but other genes also have an impact. Recent Findings Genome-wide associations studies indicate that the APOE gene, encoding apolipoprotein E (apoE), is the second most important locus modulating Lp(a) concentrations. Population studies clearly show that carriers of the apoE2 variant (ε2) display reduced Lp(a) levels, the lowest concentrations being observed in ε2/ε2 homozygotes. This genotype can lead predisposed adults to develop dysbetalipoproteinemia, a lipid disorder characterized by sharp elevations in cholesterol and triglycerides. However, dysbetalipoproteinemia does not significantly modulate circulating Lp(a). Mechanistically, apoE appears to impair the production but not the catabolism of Lp(a). Summary These observations underline the complexity of Lp(a) metabolism and provide key insights into the pathways governing Lp(a) synthesis and secretion.